The head of global research and executive vice president of Atara Biotherapeutics discussed the upcoming study evaluating ATA188.
Jakob Dupont, MD
Advertisement
Articles by Jakob Dupont, MD
The head of global research and executive vice president of Atara Biotherapeutics discussed improvements seen in patients treated with the investigational therapy.
The head of global research and executive vice president of Atara Biotherapeutics discussed the trial design of part 2 of the study of ATA188.
The executive vice president and head of global research and development at Atara Biotherapeutics spoke to the findings of a phase 1 study of the cell therapy ATA188.
Advertisement
Latest Updated Articles
Jakob Dupont, MD: Phase 1 Data on Cell Therapy for Progressive MSPublished: September 16th 2020 | Updated:
Developing Cell Therapy for Progressive MS: Jakob Dupont, MD, MAPublished: June 19th 2021 | Updated:
- ATA188’s Potential in Progressive MS: Jakob Dupont, MD, MA
Published: June 2nd 2021 | Updated:
- Evaluating ATA188 in Progressive MS: Jakob Dupont, MD, MA
Published: May 28th 2021 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency
2
New Study to Assess Complement Inhibitor Iptacopan in Generalized Myasthenia Gravis
3
Evolving Landscape of Myasthenia Gravis Treatment and Unmet Needs: Leila Darki, MD
4
Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS
5
